Trending Stocks on Tuesday: Top 10 Gainers
According to RBC Capital Markets, investors who are bullish about US equities over a course of the "next six months to a year have nearly vanished” as the Federal Reserve tightens its monetary policy...
Arcus Biosciences Inc. (RCUS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Partner Fund Management Christopher Medlock James | 2,703,287 | $55,903,975 | -21% | 2% |
| 2. | Octagon Capital Advisors Ting Jia | 2,482,700 | $51,342,236 | -7% | 7.99% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,303,520 | $47,636,794 | -16% | 2.01% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,201,150 | $24,839,782 | 0.33% | |
| 5. | Citadel Investment Group Ken Griffin | 643,229 | $13,301,976 | +2329% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.37 | 4,133 | Director | 7,133 | 2021-04-23 | Filing | |
| $28.35 | 20,000 | Director | 102,106 | 2021-03-31 | Filing | |
| $39.00 | 5,650,000 | Large Shareholder | 13,913,029 | 2021-01-31 | Filing | |
| $21.57 | 5,000 | Officer | 5,000 | 2020-09-09 | Filing | |
| $23.38 | 32,050 | Officer, Director | 3,231,179 | 2020-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.81 | 8,729 | Officer, Director | 406,217 | 2023-03-16 | Filing | |
| $23.52 | 1,600 | Officer, Director | 414,946 | 2023-01-27 | Filing | |
| $23.56 | 300 | Officer, Director | 416,546 | 2023-01-26 | Filing | |
| $31.23 | 387 | Officer | 11,566 | 2022-12-16 | Filing | |
| $30.66 | 2,066 | Officer | 11,953 | 2022-12-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 9,389,048 | $194,165,510 | 0% | |
| 2. | 4,373,177 | $90,437,300 | 0% | |
| 3. | 3,544,283 | $73,295,772 | 0% | |
| 4. | 3,315,812 | $68,570,992 | 0% | |
| 5. | 1,612,077 | $33,337,752 | 17.73% |
News See All
Hedge Funds Are Selling Arcus Biosciences, Inc. (RCUS)
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious...
10 Best Biotech Stocks to Buy According to Mark Lampert's Biotechnology Value Fund
In this article, we discuss the 10 best biotech stocks to buy according to Mark Lampert.
Hedge Funds Are Cashing Out Of Arcus Biosciences, Inc. (RCUS)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund and Insider Trading News: Carl Icahn, Steve Cohen, Alden Global Capital, Archegos Capital, Apollo Global Management, Arcus Biosciences Inc (RCUS), Starbucks Corporation (SBUX), and More
NEW YORK (Reuters Breakingviews) - DEALING AND WHEELING. Carl Icahn’s listed fund has a new leading man.
Hedge Funds Keep Buying Arcus Biosciences, Inc. (RCUS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Did Hedge Funds Make The Right Call On Arcus Biosciences, Inc. (RCUS) ?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Have Never Been This Bullish On Arcus Biosciences, Inc. (RCUS)
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March...
Is Arcus Biosciences, Inc. (NYSE:RCUS) A Good Stock To Buy?
Does Arcus Biosciences, Inc. (NYSE:RCUS) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company.
Billionaire Hedge Funds
